Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

7.8K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
7.8K
Gonadal and Placental Hormones01:24

Gonadal and Placental Hormones

4.2K
The gonads, namely the testes in males and the ovaries in females, are pivotal in producing gonadal hormones that orchestrate the intricate processes of sexual development and reproduction.
In males, testosterone is the primary gonadal androgen. It plays a central role in the maturation of male reproductive organs — the penis and testes. Additionally, testosterone is instrumental in the development of secondary sexual characteristics — a deep voice as well as facial and pubic hair...
4.2K
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

2.4K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
2.4K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

782
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
782
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

2.1K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Structured counselling and its association with IVF cycle cancellations and patient adherence.

Reproductive biomedicine online·2026
Same author

Follicular development during the follicular phase of the menstrual cycle: the enigma of luteinizing hormone receptor function.

Frontiers in endocrinology·2026
Same author

Helping patients achieve their expected live birth rate: an ART paradigm shift.

Reproductive biomedicine online·2026
Same author

International Expert Consensus Statement on Chronic Endometritis: A Comprehensive Literature Review and Modified e-Delphi Study.

Reproductive medicine and biology·2026
Same author

Beyond treatment: making obesity prevention central to reproductive health and reducing pregnancy loss.

Fertility and sterility·2026
Same author

Rethinking the route of oocyte retrieval: when one procedure does not fit all.

Reproductive biomedicine online·2026

Related Experiment Video

Updated: Apr 14, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

8.1K

The updated Cochrane review 2014 on GnRH agonist trigger: repeating the same errors.

Shahar Kol1, Peter Humaidan2, Birgit Alsbjerg2

  • 1IVF Unit, Rambam Health Care Campus, The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Reproductive Biomedicine Online
|April 21, 2015
PubMed
Summary

Gonadotrophin-releasing hormone agonist (GnRHa) triggers may not lower pregnancy chances in IVF. A recent Cochrane review repeated errors by combining studies with different luteal support, obscuring the true impact of GnRHa triggers.

Keywords:
Cochrane reviewGnRHa triggeringluteal supportmeta-analysis

More Related Videos

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.8K
Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
08:39

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Published on: May 16, 2022

3.2K

Related Experiment Videos

Last Updated: Apr 14, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

8.1K
Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies
06:24

Establishment of Rat Models Mimicking Gender-affirming Hormone Therapies

Published on: January 10, 2025

1.8K
Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
08:39

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents

Published on: May 16, 2022

3.2K

Area of Science:

  • Reproductive Endocrinology
  • Evidence-Based Medicine
  • In Vitro Fertilization

Background:

  • Cochrane reviews set the standard for evidence-based health care.
  • Previous reviews on gonadotrophin-releasing hormone agonist (GnRHa) triggers in IVF have been conducted.
  • A recent updated Cochrane review concluded GnRHa triggers reduce pregnancy rates in fresh autologous IVF and intracytoplasmic sperm injection cycles.

Purpose of the Study:

  • To critically evaluate the methodology and conclusions of a recent Cochrane review on GnRHa triggers.
  • To question the validity of conducting systematic reviews during early research phases.
  • To highlight potential flaws in comparing studies with heterogeneous luteal phase protocols.

Main Methods:

  • Analysis of the methodology used in the updated Cochrane review.
  • Critique of the inclusion criteria and data synthesis of the reviewed studies.
  • Examination of the impact of luteal phase support on pregnancy rates in IVF.

Main Results:

  • The updated Cochrane review potentially repeated errors from previous analyses by including non-comparable studies.
  • Different luteal phase protocols used across studies confound the interpretation of GnRHa trigger efficacy.
  • Luteal support, not the GnRHa trigger, is identified as the primary variable affecting pregnancy rates.

Conclusions:

  • The updated Cochrane review's conclusions regarding GnRHa triggers may be unreliable due to methodological limitations.
  • Meaningful comparisons require outcome measures unaffected by variations in luteal support.
  • The review failed to address fundamental clinical questions regarding GnRHa triggers in assisted reproduction.